OUR FACILITIESOUR CDMO

Make your life simple
One partner for every step of your program
bt_bb_section_bottom_section_coverage_image

PROCESS DEVELOPMENT

Microbiotic Candidates

Aerobic & anaerobic
Consortia & multi or single strains
Commensal and delivery GMO
Post-biotic

R&D Microbiology Platform

Risk group assessment (Bioinformatics)
Strain isolation & characterization: screening,
strain-specific ID (molecular tools), strain characterization
Analytical methods, transfer, development and validation

R&D Process Platform

Manufacturability screening and process development
Fermenters: 0.5L, 2L, 5L, 20L, 150L
Centrifugation & TFF
Freeze-driers : 2 x 0.5m² – 1.5m² – 4m²
Dosage forms : capsules, tablets, sticks, oil suspensions and creams
Powder and product characterization
Comparability tests

humility

efficiency

expertise

agility

https://www.biose.com/wp-content/uploads/2021/05/biose-gelule-microbiom.jpg
https://www.biose.com/wp-content/uploads/2021/05/biose-gelule-microbiom-aurillac.jpg
https://www.biose.com/wp-content/uploads/2021/05/biose-gelule-microbiom-aurillac-cdmo.jpg

GMP DRUG SUBSTANCE

Cell banking

GMP MCB and WCB manufacturing
according to LBP guidelines
and storage at -80°C and -20°C

Scale-up & manufacturing

DS1 : 300L and 3 500L – Centrifugation & TFF + 25m² freeze-dryer
DS2 : 2 000L – dedicated Lcr35 – Concentration + 6m² freeze-dryer
DS3 : 4 x 800L – dedicated Lcr35 – 2x 30m² freeze-dryer
DS4 : 150L – Centrifugation + 1m² freeze-dryer
DS5 : 2 000L – Centrifugation + 12m² freeze-dryer
DS6 : 5 000L – Centrifugation + 30m² freeze-dryer
Commercial or clinical batches released by our QP (PharmD)
Powder placebo production for capsules, tablets and sachets

35 M€ investment over
the next 4 years to maintain
our position as the world
leading CDMO for LBPs

https://www.biose.com/wp-content/uploads/2021/05/biose-microbiotic.jpg

35 M€ investment over

the next 4 years to maintain

our position as the world

leading CDMO for LBPs

GMP DRUG PRODUCT

Candidate strains

Aerobic & anaerobic
Consortia & single strains
Commensal and GMO organisms

Scale-up & manufacturing

Formulation and excipient screening and placebo
formulation for capsules, tablets, sachets, oils and creams
Blending from 10 to 400 kg
Dosage forms : capsules, tablets and powder
Enteric banding and coating
Packaging : blisters, vials, sachets,
tubes, creams and oils

In 2020

55 tonnes of DS
100 million capsules
10 million sticks

Many clinical batches for Europe and US

bt_bb_section_top_section_coverage_image